Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 1/20 | 0.79 |
| ▸ | MAPT | P10636 | 6/20 | 0.65 |
| ▸ | HPGD | P15428 | 6/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23542279 | 0.90 | MMP9 (0.81) | MMP9MAPTHPGDLMNASMN1; SMN2 | |
| SCHEMBL23542311 | 0.90 | MAPT (0.80) | MMP9MAPTHPGDLMNASMN1; SMN2 | |
| SCHEMBL27397745 | 0.89 | MMP9 (0.70) | MMP9MAPTHPGDLMNASMN1; SMN2 | |
| SCHEMBL23542309 | 0.89 | HPGD (0.78) | MMP9MAPTHPGDLMNASMN1; SMN2 | |
| SCHEMBL27397748 | 0.89 | MMP9 (0.70) | MMP9MAPTHPGDLMNASMN1; SMN2 | |
| SCHEMBL20510185 | 0.88 | MMP9 (1.00) | MMP9MAPTHPGDLMNASMN1; SMN2 | |
| SCHEMBL20510321 | 0.88 | MMP9 (0.81) | MMP9MAPTHPGDLMNASMN1; SMN2 | |
| SCHEMBL23542308 | 0.88 | MMP9 (0.69) | MMP9MAPTHPGDLMNASMN1; SMN2 | |
| SCHEMBL23542285 | 0.86 | MMP9 (0.69) | MMP9MAPTHPGDLMNASMN1; SMN2 | |
| SCHEMBL23542278 | 0.86 | MMP9 (0.77) | MMP9MAPTHPGDLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018003-B2 | Substituted pyrimidines as matrix metalloproteinase-9 hemopexin domain inhibitors | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2024-06-25 | — | — | US | disclosed |
| US-12018003-B2 | Substituted pyrimidines as matrix metalloproteinase-9 hemopexin domain inhibitors | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2024-06-25 | — | — | US | disclosed |
| US-20210309616-A1 | SUBSTITUTED QUINAZOLINES AS MATRIX METALLOPROTEINASE-9 HEMOPEXIN DOMAIN INHIBITORS | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK | 2021-10-07 | — | — | US | disclosed |
| US-11040947-B2 | Substituted quinazolines as matrix metalloproteinase-9 hemopexin domain inhibitors | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2021-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12018003-B2 | Substituted pyrimidines as matrix metalloproteinase-9 hemopexin domain inhibitors | MMP9, MMP7, MMP11 | MMP9 1/4885MAPT 422/4885HPGD 259/4885 |
| US-20210309616-A1 | SUBSTITUTED QUINAZOLINES AS MATRIX METALLOPROTEINASE-9 HEMOPEXIN DOMAIN INHIBITORS | MMP2, MMP9, MMP10 | MMP9 2/4885MAPT 4268/4885HPGD 171/4885 |
| US-11040947-B2 | Substituted quinazolines as matrix metalloproteinase-9 hemopexin domain inhibitors | MMP2, CBR3, NR4A3 | MMP9 14/4885MAPT 4861/4885HPGD 559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.